Cardiometabolic outcomes of sitagliptin-enhanced metformin treatment in uncontrolled type 2 diabetes patients without atherosclerotic manifestations

E.-D. Grigorescu, C.-M. Lăcătușu,M. Floria,G.-D. Cazac,A. Onofriescu,V. Șorodoc,A. Ceasovschih, L. Șorodoc, B.-M. Mihai

Atherosclerosis（2023）

引用 0|浏览1

暂无评分

摘要

Background and Aims: Type 2 diabetes mellitus (T2DM) contributes to the development and progression of subclinical diastolic dysfunction (DD) as incipient myocardial damage. This study assessed the cardio-metabolic outcomes of sitagliptin added to metformin treatment in uncontrolled T2DM patients without atherosclerotic manifestations.

查看译文

关键词

metformin treatment,diabetes patients,cardiometabolic outcomes,sitagliptin-enhanced

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要